CD38, an enzyme involved in neuroinflammation and cellular senescence, has recently been implicated in these processes. However, its specific role in CEC dysfunction within the context of VaD remains ...

Plasma cell populations can be identified based on the expression of CD45, CD38, and the more plasma cell-specific marker CD138. These markers allow plasma cells to be classified as either normal ...

The immunophenotype of tumor cells includes strong ALK expression (ALK gene rearrangement) and expression of plasma-cell markers CD38, CD138, and VS38C. CD20a, Pax-5, CD79, and B-cell markers are ...

The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy targeting CD38 and developed using the THANK-uCAR platform, in an investigator ...

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumours, announces that KJ-C2320, an allogeneic CAR ...

Acute promyelocytic leukemia (APL) presenting solely as myeloid sarcoma (MS) is extremely rare. This report describes a 53-year-old male who presented with low back pain and a movement disorder in his ...

an allogeneic CAR T-cell therapy targeting CD38, has administered the first dose to a patient in an investigator-initiated trial (IIT). KJ-C2320 is developed based on CARsgen’s THANK-uCAR ® platform.